Abbott Laboratories stock (US0028241000): U.S. healthcare name steadies after recent slide as institutional investors add exposure

Abbott Laboratories shares on the NYSE traded slightly lower on 06/02/2026 even as recent filings show U.S. institutions adding to positions in the healthcare group. The move comes after a weaker share-price run over the past year and ahead of the company’s next earnings update.

Abbott Laboratories shares in the United States continued to consolidate at the start of June, with the NYSE-listed stock closing at USD 86.97 on 06/02/2026, down 0.92% for the day according to Charles Schwab data as of that date.

The movement leaves the healthcare name well below its 52-week high of around USD 139.06, underlining a softer price performance over the past 12 months even as the company maintains solid profitability and a large-cap profile on the U.S. market.

Based on trading data cited by Charles Schwab, the 06/02/2026 session saw a volume of just over 10 million Abbott Laboratories shares change hands on the New York Stock Exchange, reflecting continued liquidity in one of the country’s major healthcare stocks.

In terms of valuation, figures compiled by Stock Analysis indicate that Abbott Laboratories carried a market capitalization of roughly USD 151.49 billion as of 06/02/2026, compared with a level about 35% higher one year earlier, highlighting the market’s repricing of the stock over that period.

These price and market-cap dynamics on the NYSE frame the backdrop for fresh institutional activity in the United States, where large asset managers continue to adjust their exposure to the company ahead of its next scheduled earnings event.

A recent filing summarized by MarketBeat on 06/03/2026 reported that Marble Wealth LLC opened a new position of 13,216 Abbott Laboratories shares during the fourth quarter, an investment valued at approximately USD 1.66 million at the time, signalling ongoing interest from U.S.-based institutional investors.

On the same day, another MarketBeat report noted that Bank of New York Mellon Corp, one of the larger custodial banks in the United States, increased its holdings in Abbott Laboratories, adding to evidence that large financial institutions remain engaged with the stock.

While individual filings account for only a small portion of the overall shareholder base, the combination of these U.S. Securities and Exchange Commission disclosures underscores that institutional ownership continues to play a central role in the company’s investor structure.

Fund managers are making these allocation decisions against the backdrop of Abbott Laboratories’ latest reported financial performance, where the company’s medical devices, diagnostics, nutrition and established pharmaceuticals units collectively delivered mid-single-digit revenue growth in the most recently reported quarter.

According to MarketBeat’s summary of recent results, Abbott Laboratories generated quarterly revenue of about USD 11.16 billion, up 7.8% compared with the same period a year earlier, and posted a net margin of 13.90% alongside a return on equity of 17.62%, indicating a business that remains solidly profitable.

Those margins, paired with the company’s long-standing dividend track record, help explain why the stock continues to feature prominently in U.S. institutional portfolios, even though the share price has not kept pace with some of the faster-growing names in the healthcare sector over the past year.

At the same time, consensus data aggregated by MarketBeat as of early June 2026 show that the stock carries an overall rating of "Moderate Buy" from covering analysts, alongside an average price target of roughly USD 119.09, supporting the picture of a company that remains broadly favored by Wall Street research desks.

Home-market investors in the United States are therefore balancing the recent share-price softness with the company’s stable profitability metrics and dividend profile as they position portfolios ahead of Abbott Laboratories’ next earnings date, which Stock Analysis lists as 04/16/2026 for the most recent confirmed update in the calendar.

In Germany, Abbott Laboratories can also be traded via platforms such as Tradegate, giving European investors an additional channel to access the U.S.-listed stock in euros during extended hours, although liquidity and spreads typically remain centered on the New York Stock Exchange.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Healthcare - medical devices, diagnostics and nutrition
• Headquarters/country: Abbott Park, United States
• Core markets: North America, Europe, Asia-Pacific and Latin America
• Key revenue drivers: Medical devices, diagnostics, nutrition products and established pharmaceuticals
• Home exchange/listing venue: New York Stock Exchange (ABT)
• Trading currency: USD

Abbott Laboratories: core business model

Abbott Laboratories focuses on creating and commercializing medical devices, diagnostics systems, nutrition brands and established pharmaceutical products that aim to support patient care across both developed and emerging markets.

Abbott Laboratories in peer comparison

Measured against other large U.S.-listed healthcare names, Abbott Laboratories sits in the same broad segment as diversified medical-technology and diagnostics groups such as Johnson & Johnson, Medtronic and Becton Dickinson, which all operate across multiple product lines and geographies.

Many of these peers likewise report double-digit returns on equity and mid-single-digit to high-single-digit revenue growth, and market data show that Abbott Laboratories’ margin profile and global reach are broadly comparable, even though individual product exposures and regulatory pipelines differ across companies.

Conclusion

Abbott Laboratories’ share price on the New York Stock Exchange remains below its 52-week high, even as institutional investors in the United States continue to adjust positions based on the company’s steady profitability and dividend record.

The peer comparison within the broader U.S. healthcare and medical-technology space suggests that the group’s margin profile and diversified business mix remain competitive, leaving investors focused on execution in key product lines and the pace of any recovery in the share price.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.